Last reviewed · How we verify
Still's disease
Approved treatments
- Anakinra · Biovitrum Ab
- Roactemra · Roche
Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation. - Kineret · Biovitrum Ab
Kineret blocks the action of interleukin-1, a protein that promotes inflammation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Still's disease patent landscape — cliff calendar, originator estates, attackable patents
- Still's disease treatment landscape brief
- Still's disease treatment updates RSS
Frequently asked questions about Still's disease
What drugs treat Still's disease?
Tracked treatments include Anakinra, Roactemra, Kineret.
What is the treatment for Still's disease?
Standard treatment for Still's disease includes Anakinra, Roactemra, Kineret. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Still's disease patent cliff · Still's disease CI report
- Treatment: Anakinra · Biovitrum Ab
- Treatment: Roactemra · Roche
- Treatment: Kineret · Biovitrum Ab
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing